Medical Advocates
Efavirenz (Sustiva/Strocrin)
 
Perinatal Index

FDA Alerts/ Label Revisions
Guidelines and Recommendations
 Journal Citations
 Conference Citations



 


 
Efavirenz Main Page Main New/Newsworthy  Home Page      
Last Update:  November 16, 2011
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
FDA Alerts/Label Revisions
       
Journal Papers, Abstracts, and Commentaries
       
 
Efavirenz Pharmacokinetics during the Third Trimester of Pregnancy and Postpartum.
Cressey TR, Stek A, Capparelli E, et al
J Acquir Immune Defic Syndr. 2011 Nov 11.
 Abstract

Safety of efavirenz in first-trimester of pregnancy: an updated systematic review and meta-analysis.
 Ford N, Calmy A, Mofensen L.
AIDS. 2011 Sep 13
 Abstract

Efavirenz-based combination antiretroviral therapy after peripartum single-dose nevirapine.
 Bolhaar MG, Karstaedt AS.
 Int J STD AIDS. 2011 Jan;22(1):38-42
 Abstract

Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA
West Africa and ANRS databases, Abidjan, Côte d'Ivoire.
 Ekouevi DK, Coffie PA, Ouattara E,  et al
J Acquir Immune Defic Syndr. 2010 Nov 13.
 Abstract

Safety of efavirenz in first-trimester of pregnancy: a systematic review and
meta-analysis of outcomes from observational cohorts.
 Ford N, Mofenson L, Kranzer K,  et al 
AIDS. 2010 May 14.
 Abstract

Efavirenz in Human Breast Milk, Mothers', and Newborns' Plasma.
 Schneider S, Peltier A, Gras A, et al 
J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):450-454
 Abstract
Prevention/Treatment Guidelines and Recommendations
United States      
United States

     Internet Documents
 
  FULL-TEXT PDF DOCUMENT
 Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in
Pregnant HIV- 1-Infected Women for Maternal Health and Interventions to Reduce Perinatal
HIV-1Transmission  in the United States 
 Public Health Service Task Force 
October 12, 2006
 PDF Guidelines
 
  FULL-TEXT PDF DOCUMENT
 Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy
 Public Health Service Task Force 
October 12, 2006
PDF Guidelines

Conference Citations
       
 
Pregnancy, Efavirenz, and Birth Outcomes in Johannesburg
 D Westreich, D Rubel, P MacDonald, et al
 (17th CROI)
 Abstract

POSTER
 Efavirenz conceptions in Soweto, South Africa
F. Laher, J. Forrest, L. Mohapi, G. Gray
 (5th IAS Conference)
PDF Poster     Abstract

Efavirenz in pregnancy: maternal characteristics of women who become pregnant on
EFV-containing regimen and neonatal effects
 M.I. Gonzalez-Tome, M. Fernandez-Ibieta J. Ramos Amador et al
 (XVII International AIDS Conference)
 Abstract
 
Increased incidence of spontaneous abortion during first trimester exposure to efavirenz
 Joao E , Calvet G , Sidi L,  et al
(4th IAS Conference)
 Abstract
 
POSTER
 Pregnancy Outcomes of Women Receiving Efavirenz after the First Trimester
 N Phanuphak, T Apornpong, S Limpongsanurak, et al
 (14 CROI)
PDF Poster    Abstract
 
Efavirenz during the second half of pregnancy is safe for infants of HIV -infected women
Collins J.A., Allauja M., Castromonte M.
 (XVI IAC)
 Abstract
 
Pregnancy outcome in women exposed to efavirenz
Joao E.C., Calvet G.A., Cunha C.B., et al
 (XVI IAC)
 Abstract

Plasma Concentrations of Efavirenz (EFV) in Pregnant HIV-infected Women
Treated with EFV Containing Regimen.
Cassard B., Rouault A., Damond F., et al
(3rd IAS Conference)
 Abstract

Efavirenz Main Page Main New/Newsworthy  Home Page      

  Efavirenz Perinatal Index